Diligence memo · auto-generated · as of July 2, 2026

Proactive Diagnostics, Inc.

Proactive Diagnostics, Inc. looks over-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Proactive Diagnostics, Inc. operates in Biotechnology, based in THOUSAND OAKS.

Sub-sector tags: medical-devices.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Proactive Diagnostics, Inc. has raised $2.0M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $2.0M on 2022-10-28.

Most recent recorded round closed around 2022-10-28.

Valuation (modeled)modeled

Provath models Proactive Diagnostics, Inc. at approximately $25M (range $1.4M–$103M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 1.72× the median modeled value of Seed Biotechnology companies in 2022–2024 (207 peers) — value vs value, same stage and era. Issuer reports no revenue, yet is modeled well above niche peers.

Financing rhythm & timingmixed

Last raise 3.7 yr ago; this sector typically re-raises about every 14 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 28% of Biotechnology peers (4293 compared).

Modeled value ranks above 32% of those peers.

Closest niche peers: Mesentech Inc., Marlinspike Therapeutics, Inc., Microbial Machines, Inc., Pearl Diagnostics, Inc., Crossfire Medical Inc.

Peoplefiled

1 named person on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.